Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs.
September 29, 2022 Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 16, 2022 Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)